Industry News

Biotechnology Industry News

Ambrosia Biosciences is aiming to…

March 31st, 2026|FierceBiotech|

Ambrosia Biosciences is aiming to move the market beyond peptide-based obesity treatments and initiate a trial for its oral small-molecule GLP-1 therapy, backed by an oversubscribed $100 million series B round.

A phase 3 trial of AstraZeneca’s…

March 31st, 2026|FierceBiotech|

A phase 3 trial of AstraZeneca’s rare metabolic disease prospect has missed its primary endpoint, raising doubts about the company’s ability to expand beyond the children served by its existing drug.

Lipella Pharmaceuticals’…

March 31st, 2026|FierceBiotech|

Lipella Pharmaceuticals’ ambition to develop the first treatment for an inflammatory mouth condition has reached the end of the road, with the biotech filing for bankruptcy.

Astellas Pharma has become the…

March 30th, 2026|FierceBiotech|

Astellas Pharma has become the latest company to pull back from a potential treatment for Sjögren’s syndrome, an autoimmune disease that still lacks any dedicated medicines.

One of the world’s leading…

March 30th, 2026|FierceBiotech|

One of the world’s leading investment firms has broken its own record with the closing of its $6.3 billion Blackstone Life Sciences VI (BLXS VI) fund, which is 40% larger than its predecessor.

Autoimmune specialist Aurinia,…

March 30th, 2026|FierceBiotech|

Autoimmune specialist Aurinia, which named Kevin Tang as its new CEO last week, is acquiring Kezar after the latter company received promising feedback from the FDA. Tang previously made an unsuccessful attempt in 2024 to

Royalty Pharma has made another…

March 30th, 2026|FierceBiotech|

Royalty Pharma has made another play in the autoimmune space, this time crowning Johnson & Johnson as the beneficiary. Royalty and J&J have agreed to co-fund the development of a chronic autoimmune disease treatment, with

Connect Biopharma has reported…

March 30th, 2026|FierceBiotech|

Connect Biopharma has reported 52-week improvements across multiple endpoints in a phase 3 trial of its eczema drug candidate, fueling the biotech’s belief that its molecule is better than Dupixent.

Biogen’s lupus drug candidate…

March 30th, 2026|FierceBiotech|

Biogen’s lupus drug candidate litifilimab has improved outcomes in another phase 2 trial, adding to the momentum behind a program barreling toward pivotal data in two forms of the autoimmune disease.

Kailera Therapeutics—one of the…

March 30th, 2026|FierceBiotech|

Kailera Therapeutics—one of the biggest money-raisers of 2025—is now seeking to go public as it seeks further funding to push its obesity portfolio through the clinic.

In the early 1960s, Norwegian…

March 29th, 2026|FierceBiotech|

In the early 1960s, Norwegian physician Kåre Berg, M.D., was trying to identify new blood types when he accidentally discovered a lipoprotein with perplexing properties.

KBP Biosciences is looking to…

March 27th, 2026|FierceBiotech|

KBP Biosciences is looking to reclaim ownership of the ill-fated heart drug ocedurenone from Novo Nordisk following a botched $1.3 billion deal and fraud allegations, Fierce Biotech has learned.

Eli Lilly and AI-powered…

March 27th, 2026|FierceBiotech|

Eli Lilly and AI-powered clinical-stage biotech Insilico Medicine have announced a back-loaded, $2.75 billion biobucks drug discovery collaboration that will extend the Big Pharma company’s access to Insilico’s AI engine to pursue novel therapeutics.